Disclaimer:
For research use only. Not for human consumption. Intended for laboratory-based studies by qualified professionals. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
 
 
Overview:
Sermorelin is a synthetic growth hormone–releasing hormone (GHRH 1–29) analog studied for its ability to stimulate the natural production and release of growth hormone (GH) from the pituitary gland. It represents the biologically active fragment of endogenous GHRH and is widely used in research exploring endocrine regulation, aging, and metabolic function.
Mechanism of Action:
Sermorelin binds to GHRH receptors in the anterior pituitary, triggering the synthesis and pulsatile release of endogenous GH. This natural rhythmic stimulation supports the body’s physiological feedback mechanisms, leading to increased insulin-like growth factor 1 (IGF-1) production and enhanced anabolic signaling. In contrast to synthetic GH administration, Sermorelin promotes endogenous GH regulation, preserving receptor sensitivity and physiological balance in research models.
Research Highlights:
Demonstrated increased GH and IGF-1 secretion in preclinical and human studies.
Studied for potential applications in metabolic optimization, tissue repair, and anti-aging research.
Shown to maintain normal feedback regulation and pulsatile GH secretion patterns.
Often compared to or combined with GHRPs (such as Ipamorelin or GHRP-6) for synergistic GH release studies.
Specifications:
Form: Lyophilized powder (research-grade)
Purity: ≥98% (HPLC-tested)
Storage: Store refrigerated (2–8 °C), protected from moisture and light.